Selective Serotonin Reuptake Inhibitor (SSRI) Bleeding Risk: Considerations for the Consult-Liaison Psychiatrist

Daniel McFarland, Dale Merchant, Abhisek Khandai, Mona Mojtahedzadeh, Omar Ghosn, Jeremy Hirst, Hermioni Amonoo, Depti Chopra, Shehzad Niazi, Jennifer Brandstetter, Andrew Gleason, Garrett Key, Barbara Lubrano di Ciccone

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: To present a clinically oriented review of selective serotonin reuptake inhibitor (SSRI)-related bleeding issues commonly addressed by consult-liaison psychiatrists. Recent Findings: Concomitant medical, surgical, or hospital-based conditions exacerbate the risk of SSRI-related bleeding even though a review of the literature suggests it is only marginally elevated. Psychiatrists and other clinicians need to consider these conditions along with antidepressant benefits when answering the question: to start, hold, continue, or change the antidepressant? Summary: Where an evidence base is limited, mechanistic understanding may help consult-liaison psychiatrists navigate this terrain and collaborate with other medical specialties on responsible antidepressant management. Most often, the risk is cumulative; data are not directly applicable to complex clinical situations. This review incorporates a hematologic perspective and approach to bleeding risk assessment along with extant data on SSRI-induced bleeding risk ad specific medical conditions.

Original languageEnglish (US)
Pages (from-to)113-124
Number of pages12
JournalCurrent psychiatry reports
Issue number3
StatePublished - Mar 2023


  • Antidepressant side effects
  • Bleeding risk
  • Hemorrhage
  • Medically complex patients
  • Serotonin reuptake inhibitor
  • Thrombocytopenia

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Selective Serotonin Reuptake Inhibitor (SSRI) Bleeding Risk: Considerations for the Consult-Liaison Psychiatrist'. Together they form a unique fingerprint.

Cite this